Diagnostic and therapeutic caveats in Griscelli syndrome

Scand J Immunol. 2021 Jun;93(6):e13034. doi: 10.1111/sji.13034. Epub 2021 Mar 20.

Abstract

Griscelli syndrome (GS) is a rare autosomal recessive disease with characteristic pigment distribution, and there are currently 3 types according to the underlying genetic defect and clinical features. We present the case of a girl born from consanguineous parents who presented with predominant neurologic symptoms, silvery hair and granulomatous skin lesions. Cerebral magnetic resonance revealed diffuse white matter lesions, and central nervous system (CNS) lymphocytic infiltration was suspected. The patient underwent haematopoietic stem cell transplantation with graft failure and autologous reconstitution. She developed elevated liver enzyme with a cholestatic pattern. Multiple liver biopsies revealed centrilobular cholestasis and unspecific portal inflammation that improved with immunomodulatory treatment. She was revealed to have an impaired cytotoxicity in NK cells and a decreased expression of RAB27A. However, no variants were found in the gene. All types of GS present with pigment dilution and irregular pigment clumps that can be seen through light microscopy in hair and skin biopsy. Dermic granulomas and immunodeficiency with infectious and HLH predisposition have been described in GS type 2 (GS2). Neurologic alterations might be seen in GS type 1 (GS1) and GS type 2 (GS2), due to different mechanisms. GS1 presents with neurologic impairment secondary to myosin Va role in neuronal development and synapsis. Meanwhile, GS2 can present with neurologic impairment secondary to SNC HLH. Clinical features and cytotoxicity might aid in differentiating GS1 and GS2, especially since treatment differs.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Biomarkers
  • Biopsy
  • Disease Management
  • Disease Susceptibility / immunology
  • Genetic Predisposition to Disease
  • Hearing Loss, Sensorineural / diagnosis*
  • Hearing Loss, Sensorineural / etiology
  • Hearing Loss, Sensorineural / therapy*
  • Humans
  • Lymphohistiocytosis, Hemophagocytic / diagnosis*
  • Lymphohistiocytosis, Hemophagocytic / etiology
  • Lymphohistiocytosis, Hemophagocytic / therapy*
  • Mutation
  • Phenotype
  • Piebaldism / diagnosis*
  • Piebaldism / etiology
  • Piebaldism / therapy*
  • Pigmentation Disorders / diagnosis*
  • Pigmentation Disorders / etiology
  • Pigmentation Disorders / therapy*
  • Primary Immunodeficiency Diseases / diagnosis*
  • Primary Immunodeficiency Diseases / etiology
  • Primary Immunodeficiency Diseases / therapy*
  • Prognosis

Substances

  • Biomarkers

Supplementary concepts

  • Griscelli syndrome type 1
  • Griscelli syndrome type 2
  • Griscelli syndrome type 3